Ochre Bio
Clinical-stage biotechnology company developing RNA medicines for chronic liver diseases using its deep phenotyping platform to identify and validate therapeutic targets.
Website
https://www.ochrebio.comLocation
Oxford, United Kingdom & New York, USA
Founded
2019
Investors
1
Categories
biotech, liver-disease, rna-medicines, phenomics
Notes
Ochre Bio is a clinical-stage biotechnology company developing RNA medicines to rejuvenate livers and treat chronic liver diseases. The company uses its proprietary deep phenotyping platform that combines human tissue research with computational biology to discover and develop novel therapeutics.
Ochre Bio's unique approach involves researching living human livers (ex vivo) that would otherwise be discarded after transplantation to understand disease biology at unprecedented depth.
Team
- Jack O'Meara, Ph.D. - Co-Founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/jackomeara
- Quin Wills, Ph.D. - Co-Founder & Chief Scientific Officer
Additional Research Findings
- Founded in 2019 with headquarters in Oxford, UK and New York
- Portfolio company of Apollo Health Ventures
- Proprietary ex vivo human liver phenotyping platform
- Focus on RNA medicines for liver rejuvenation
- Studies discarded human livers to understand disease mechanisms
- Combines wet lab research with computational biology
- Lead programs targeting chronic liver disease indications
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Apollo Health Ventures | Dusseldorf, Germany / Boston, USA | biotech-focused | seedseries-a+1 | 15 |